Alzheimer's & Blood Testing
Alzheimer's Risk &
Blood Testing —
What You Can
Measure Right Now
Alzheimer's begins silently — up to 20 years before the first symptom. A new generation of blood tests can now detect it earlier than ever. And the modifiable risk factors that drive it? Many are measurable today. Here's everything you need to know — and act on.
The 20-Year Window
Alzheimer's Is Not a Sudden Disease. It's a Decades-Long Process.
One of the most important — and least discussed — facts about Alzheimer's disease is this: by the time someone receives a diagnosis, the brain has typically been changing for 15 to 20 years. Amyloid plaques have been accumulating. Tau tangles have been forming. Neurons have been dying. The clinical symptoms that prompt a GP visit — the memory lapses, the word-finding difficulties, the confusion — are late-stage manifestations of a process that started in middle age.
This is not cause for despair. It's cause for action. Because that two-decade window is also the window of maximum opportunity — a period during which modifiable risk factors are detectable, addressable, and genuinely impactful. The field of Alzheimer's prevention has been transformed in the last five years by two developments: first, the identification of blood biomarkers that can detect Alzheimer's pathology decades before symptoms; and second, growing evidence that lifestyle and metabolic interventions during this silent phase can meaningfully slow — or in some cases prevent — progression.
The question is no longer whether blood testing can contribute to Alzheimer's risk assessment. It clearly can. The question is what to test, when to test it, and what to do with the results.
Alzheimer's doesn't begin when the memory fails. It begins 20 years earlier — when a blood test could already be showing you something worth acting on.
The Silent Timeline
What's Actually Happening in the Brain — and When
20+ years before symptoms — p-tau217 rises first
The very first detectable Alzheimer's biomarker — p-tau217 in blood — begins to rise more than 20 years before symptom onset. This is now the earliest known window of detection. A 2025 analysis of dominantly inherited Alzheimer's disease confirmed p-tau217 shows abnormality well over 20 years before expected onset — making it the most sensitive early biomarker identified to date. Amyloid begins accumulating silently. No symptoms. But blood testing can see it.
15 years before symptoms — amyloid accumulation accelerates
Amyloid-beta plaques are now building more rapidly. The amyloid-β 42:40 ratio in blood begins to shift — reflecting increasing plaque burden. NfL (neurofilament light chain) may begin to rise, reflecting early neuronal damage. Blood cholesterol, blood sugar, and homocysteine — all measurable now — are actively influencing the pace of this accumulation. Modifiable risk factors are still highly impactful at this stage.
10 years before symptoms — tau tangles form, brain volume declines
Tau tangles begin forming. Brain volume starts to measurably decline — particularly in memory-related regions. GFAP (glial fibrillary acidic protein) — a marker of neuroinflammation and brain injury — begins to elevate in blood. A major 16-year Swedish cohort study found elevated GFAP at this stage had a predictive accuracy of up to 82.6% for future dementia. Cognitive changes are still absent or very subtle.
5 years before symptoms — mild cognitive impairment may begin
Subtle changes in memory, word-finding, or processing speed become noticeable to the individual — though not yet clinically significant. Blood biomarkers are now highly reliable. p-tau217 can predict the onset of Alzheimer's in cognitively unimpaired individuals within a 4-year window with high accuracy. Lifestyle and metabolic intervention is still meaningful — but the window is narrowing.
Symptoms appear — diagnosis begins — average 17.7 week NHS wait
Noticeable memory problems and confusion prompt a GP visit. By this point, significant neurological damage has already occurred. The UK's average wait from referral to diagnosis is now 17.7 weeks — up from 13 weeks in 2019 — with some patients waiting over two years. Treatment options are limited. The prevention window has substantially closed.
The Breakthrough Biomarkers
The Blood Tests That Are Changing Everything
The last five years have seen extraordinary advances in blood-based Alzheimer's biomarkers. What once required an invasive lumbar puncture or an expensive PET scan can now be detected from a blood sample — with accuracy that is transforming clinical practice and research.
Blood biomarker accuracy — ruling out vs predicting Alzheimer's
Source: PMC 2025 Swedish 16-year cohort study / Biomedicines 2024 p-tau217 review / Alzheimer's Association AAIC 2024. Blood biomarkers are becoming clinically viable alternatives to gold-standard but resource-intensive diagnostic methods.
What You Can Test Today
The Modifiable Risk Markers Available Right Now Through Private Testing
While specialist Alzheimer's biomarkers like p-tau217 are currently available through clinical trial settings and a small number of private specialist clinics, the modifiable risk markers — the ones that account for up to 45% of all cases — are available through standard private blood testing right now. These are where the most immediate action can be taken.
The Exercise Finding That Changes Everything
p-tau217 Responds to Exercise. That's Extraordinary.
One of the most striking findings in recent Alzheimer's research is that p-tau217 — the blood biomarker that detects Alzheimer's pathology 20 years before symptoms — is not fixed. It responds to interventions. And one of the most consistently demonstrated interventions is exercise.
Two separate studies cited in Dr Eric Topol's 2025 analysis showed that exercise reduces p-tau217 and the closely correlated p-tau181 in blood — directly reducing the measurable biological burden of Alzheimer's pathology. This is not just showing that exercise is generally good for the brain. This is showing that a specific, measurable Alzheimer's biomarker responds to physical activity.
What "dynamic" means for you
The fact that p-tau217 is dynamic — responding to both amyloid-reducing treatments and lifestyle interventions — has profound implications. It means that the biological process of Alzheimer's is not inevitable or unstoppable during the silent phase. It can be measured, monitored, and meaningfully influenced. Blood testing doesn't just tell you your risk — it gives you a tool for tracking whether what you're doing is actually working at a biological level. This is what precision brain health looks like.
Modifiable risk factors — estimated % of Alzheimer's cases they contribute to
Source: 2024 Lancet Commission on Dementia Prevention. All of the above are measurable via private blood testing — and all are meaningfully modifiable through lifestyle and targeted intervention.
Your Action Plan
What to Do — Starting Now
You don't need to wait for Alzheimer's specialist blood tests to become widely available before taking action. The modifiable risk markers are testable today. The interventions are evidence-based. And the earlier you start, the longer the window of impact.
Test homocysteine — make it your first priority
The most under-tested, most overlooked brain health marker with the most compelling intervention evidence. Test homocysteine alongside B12, folate, and B6. If homocysteine is above 10 µmol/L, high-dose B vitamin supplementation is the evidence-backed response — with the Oxford VITACOG trial showing up to 53% reduction in brain atrophy in those with elevated levels.
Know your LDL — it's the biggest newly identified modifiable risk
The 2024 Lancet Commission found high midlife LDL accounts for 7% of all dementia cases — the single largest newly identified modifiable factor. Get a full lipid profile. If LDL is above 3.0 mmol/L, dietary intervention, exercise, and medication where appropriate can meaningfully reduce your Alzheimer's risk alongside your cardiovascular risk.
Check HbA1c — catch insulin resistance early
Type 2 diabetes raises Alzheimer's risk by up to 60%. But insulin resistance — which HbA1c can detect years before a diabetes diagnosis — is already harmful to the brain. Addressing it through a lower-sugar diet, increased activity, and weight management in your 40s and 50s is one of the highest-impact Alzheimer's prevention strategies available.
Optimise vitamin D — test, target 100–150 nmol/L
Low vitamin D is associated with a 35% higher dementia risk. UK deficiency is endemic. The NHS sufficient threshold (50 nmol/L) is not the optimal threshold for brain health (100–150 nmol/L). Test, supplement to a specific target, and retest in three months. This is the fastest and simplest of the brain health interventions — and one of the most consistently supported by evidence.
Add hs-CRP and a full thyroid panel
Chronic inflammation and thyroid dysfunction are both independently linked to cognitive decline and Alzheimer's risk — and both are frequently undetected. hs-CRP reflects your systemic inflammatory burden; a full thyroid panel (TSH, Free T3, Free T4, Anti-TPO) catches subclinical dysfunction that standard TSH-only testing misses. Together they complete the most comprehensive routine brain health blood panel currently available.
Consider specialist Alzheimer's biomarker testing
p-tau217, NfL, GFAP, and amyloid ratio testing are currently available through a small number of private specialist neurology and longevity clinics in the UK, as well as through the ADAPT clinical trial. If you have a strong family history of Alzheimer's, are over 50 with modifiable risk factors, or simply want the most complete picture available, this is the next frontier — and it's becoming more accessible every year.
The ADAPT trial — and what comes next for the NHS
The Alzheimer's Society's £5 million Blood Biomarker Challenge — currently running the ADAPT trial across 19+ NHS specialist centres — is working to bring p-tau217 and other specialist markers into routine NHS care. The goal is to transform dementia diagnosis from a lengthy, invasive, specialist-only process into something as accessible as a cholesterol check at your GP. Expected timeline: routine NHS availability within 3–5 years. In the meantime, the modifiable risk markers described above are available now — and they're where the most immediate action can be taken.
You cannot choose your genes. But you can choose what you do about your cholesterol, your homocysteine, your blood sugar, and your vitamin D. And those choices, made now, matter more than most people realise.
Start Protecting Your Brain. Start With Your Numbers.
Private blood testing gives you the data to understand and address your Alzheimer's risk factors — decades before symptoms could ever appear. At Boost & Glow, we can help you take the right first steps.
Explore Boost & Glow → Ask Us a Question →This blog is for informational purposes only and does not constitute medical advice. Blood testing for Alzheimer's risk markers is not a diagnostic test for Alzheimer's disease. Specialist Alzheimer's biomarker tests (p-tau217, NfL, GFAP) should only be interpreted by qualified healthcare professionals with expertise in dementia medicine. If you have concerns about memory or cognitive function, please speak to your GP. Always consult a qualified healthcare professional before making changes to your health routine based on blood test results.
0 comments